Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

28.86 -1.15 (-3.83%)
Streaming Delayed Price Updated: 3:45 PM EDT, Jun 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗
 
Via Benzinga
News headline image
What 7 Analyst Ratings Have To Say About Stoke Therapeutics ↗
 
Via Benzinga
News headline image
Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Credit Suisse Maintains Outperform Rating for Stoke Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
6 Analysts Have This to Say About Stoke Therapeutics ↗
 
Via Benzinga
Expert Ratings for Stoke Therapeutics ↗
 
Via Benzinga
News headline image
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Participate at Upcoming March Investor Conferences
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Yum! Brands To Rally Around 20%? Here Are 10 Other Price Target Changes For Monday ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 72 companies hit new 52-week lows. 
Via Benzinga
News headline image
Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  During Tuesday's trading, 160 companies set new 52-week lows. 
Via Benzinga
News headline image
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday ↗
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday ↗
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus... 
Via Benzinga
News headline image
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target. 
Via Benzinga
News headline image
Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  Monday saw 33 companies set new 52-week lows. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Stoke Therapeutics Commences Initial-Stage Optic Nerve Disorder Study ↗
Stoke Therapeutics (NASDAQ: STOK) has enrolled first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA). 
Via Benzinga
News headline image
Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)
From Stoke Therapeutics
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.